Find examples of successful applications of products and services from Svar Life Science in the reference list below.


Gensmyr-Singer H, Werner M, Karling P | Therap Adv Gastroenterol | 2024

The drug-survival of low-dose thioguanine in patients with inflammatory bowel disease: a retrospective observational study

Swaminathan A, Borichevsky GM, et al |  Inflamm Bowel Dis | 2024

Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

Constantine-Cooke N, Monterrubio-Gómez K, et al | Clin Gastroenterol Hepatol | 2023

Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease

Gutiérrez-Díaz I, Sanz-Martinez M, et al | Eur J Pediatr | 2023

Microbial and immune faecal determinants in infants hospitalized with COVID-19 reflect bifidobacterial dysbiosis and immature intestinal immunity

Hamberg V, Wallman JK, et al | Rheumatol Int | 2023

Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis.

Hammer HB, Pedersen SL, et al | Scand J Clin Lab Invest | 2023

Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

Hemming-Harlo M, Merras-Salmio L, Nikkonen A, Kolho KL | Eur J Pediatr | 2023

Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting

Rojas Correa M, Estremera L, et al | Contemp Clin Trials Commun | 2023

DietaAnti-Inflamatoria or DAIN: A Crohn's disease management strategy tailored for Puerto Ricans

Sabino J, Tarassishin L, Eisele C, et al |  J Crohns Colitis | 2023

Influence of Early Life Factors, including Breastmilk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease

Bergqvist V, Holmgren J, et al | Aliment Pharmacol Ther | 2022

Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

Blad N, Palmqvist R, Karling P. | BMC Cancer. | 2022

Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study.

Chandrasekar N, Dehlsen K, et al | Nutrients | 2022

Blenderised Tube Feeds vs. Commercial Formula: Which Is Better for Gastrostomy-Fed Children?

Di Brizzi EV, Rocco A, et al | Biomedicines | 2022

Evaluation of the Role of Faecal Calprotectin in the Management of Psoriatic Patients under Treatment with Biologic Drugs.

Kim ES, Tarassishin L, Eisele C, et al | Gastroenterology | 2021

Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.

Kolho KL, Alfthan H. | Scand J Gastroenterol. | 2020

Concentration of fecal calprotectin in 11,255 children aged 0-18 years.

Ankersen DV, Weimers P, et al | World J Gastroenterol. | 2019

Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial

Goll R, Heitmann R, et al | PLoS One | 2019

Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.

Haisma SM, Galaurchi A, et al | PLoS One | 2019

Head-to-head comparison of three stool calprotectin tests for home use

Karling P, Lundgren D, et al |  Scand J Clin Lab Invest. | 2019

Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin.

Lundgren D, Eklöf V, et al | Scand J Gastroenterol | 2019

Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy.

Acevedo D, Salvador MP, et al |  J Clin Med Res. | 2018

Fecal Calprotectin: A Comparison of Two Commercial Enzymoimmunoassays and Study of Fecal Extract Stability at Room Temperature

Bergqvist V, Kadivar M, et al | Therap Adv Gastroenterol | 2018

Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Nation ML, Dunne EM, et al |  Sci Rep. | 2017

Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic.

Kristensen V, Lauritzen T, et al | Clin Chem Lab Med | 2016

Patient-performed extraction of faecal calprotectin

Mirsepasi-Lauridsen HC, Bachmann Holmetoft U, et al | Scand J Gastroenterol | 2016

Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease

Vinding KK, Elsberg H, et al | Inflamm Bowel Dis | 2016

Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease

Kristensen V, Klepp P, et al | J Crohns Colitis. | 2015

Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.

Kristensen V, Lauritzen T, et al | Scand J Clin Lab Invest | 2015

Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods

Soto-Méndez MJ, Romero-Abal ME et al | PLoS One | 2015

Associations among Inflammatory Biomarkers in the Circulating, Plasmatic, Salivary and Intraluminal Anatomical Compartments in Apparently Healthy Preschool Children from the Western Highlands of Guatemala

Labaere D, Smismans A, Van Olmen A, et al | United European Gastroenterol J | 2014

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

Prell C, Nagel D, et al |  BMJ Open. | 2014

Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study.

Burri E, Manz M, et al | Clin Chim Acta | 2013

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort.

Walkowiak J, Cofta S, et al | Eur Rev Med Pharmacol Sci | 2013

Phenylketonuria is not a risk factor for gut mucosa inflammation: a preliminary observation.

Komraus M, Wos H, Wiecek S, et al | Mediators Inflamm | 2012

Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease.


D'Sa S, Vos JMI, et al | Blood. | 2024

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.

Kulasekararaj AG, Lehtinen AE, et al |  Haematologica. | 2024

Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.

Lilian Hor, Jing Pan, et al | J Immunol | 2024

Molecular Interactions Required for Activation of Complement Component C2 Include Exosites Located on the Serine Protease Domain of C1s and Mannose-Binding Lectin Associated Protease-2

Liu F, Ryan ST, et al | Mol Ther. | 2024

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.

Nguyen TT, Kim TH, et al | PLoS Pathog. | 2024

A tick saliva serpin, IxsS17 inhibits host innate immune system proteases and enhances host colonization by Lyme disease agent

Vítek L, Woronyczova J, et al | Sports Med Open. | 2024

Complement System Deficiencies in Elite Athletes.

Kavanagh D, Greenbaum L.A , et al | Kidney International Reports | 2023

Design and rationale of the APPELHUS Phase 3 open-label study of Factor B inhibitor iptacopan for atypical hemolytic uremic syndrome

Agostinis C, Toffoli M, et al |  Int J Mol Sci. | 2023

Anti-Spike Antibodies Present in the Milk of SARS-CoV-2 Vaccinated Mothers Are Complement-Activating.

Bakos T, Kozma GT, et al | Biomed Pharmacother | 2023

Eculizumab suppresses zymosan-induced release of inflammatory cytokines IL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures: Relevance to cytokine storm in Covid-19

Balduit A, Bianco AM, et al | Front Immunol | 2023

Genetic bases of C7 deficiency: systematic review and report of a novel deletion determining functional hemizygosity

Baltcheva I, Bartels C, et al | Blood | 2023

Exposure-Response Relationships between the Factor B Inhibitor Iptacopan and Complement Biomarkers in Healthy Volunteers and Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G) or IgA Nephropathy (IgAN).

Bencosme-Cuevas E, Kim TK, et al | Front Cell Infect Microbiol | 2023

Ixodes scapularis nymph saliva protein blocks host inflammation and complement-mediated killing of Lyme disease agent, Borrelia burgdorferi

Broome CM, Röth A, et al | Blood Adv. | 2023

Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia.

Bulla R, Rossi L, Furlanis G,et al | Front Immunol. | 2023

A likely association between low mannan-binding lectin level and brain fog onset in long COVID patients.

Capolla S, Colombo F, De Maso L, et Lal | J Nanobiotechnology | 2023

Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles.

Chow T, Shamszad P, et al | Clin Transl Sci | 2023

First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.

Dreismann AK, Hallam TM, et al |  Immunol Rev. | 2023

Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway.

Dudler T, Yaseen S, Cummings WJ |  Front Immunol. | 2023

Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway–mediated disorders

García-González M, Gómez-Bernal F, et al | J Clin Med. | 2023

HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus.

García-González M, Gómez-Bernal F, et al | Front Immunol. | 2023

Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

Gerber, G.F., Pan, XZ., Lederman, H.M. et al |  J Clin Immunol | 2023

Novel Functional Assay to Characterize Mutations in Alternative Pathway of Complement.

González-Del-Barrio L, Pérez-Alós L,et al | FASEB J | 2023

MAP-2:CD55 chimeric construct effectively modulates complement activation

Grover A, Sankaranarayanan S, et al |  Invest Ophthalmol Vis Sci. | 2023

Pharmacokinetic and Target Engagement Measures of ANX007, an Anti-C1q Antibody Fragment, Following Intravitreal Administration in Nonhuman Primates

Hurler L, Szilágyi Á, et al | Front Immunol | 2023

Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.

Ikeda Z, Kamei T, et al | J Med Chem | 2023

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway..

Kavanagh D, Greenbaum LA, et al | Kidney Int Rep. | 2023

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.

Kawakami E, Saiki N, et al | Cell Stem Cell | 2023

Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19. Cell Stem Cell

Kelen K, Horváth O, et al | Int J Mol Sci | 2023

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP

Koller A, Szebeni J et al | Hum Vaccin Immunother. | 2023

Covid-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy.

McBride HJ, Frazer-Abel A, et al | Ann Hematol | 2023

Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD.

Mercader-Salvans J, García-González M, et al | Biomedicines | 2023

Blood Composite Scores in Patients with Systemic Lupus Erythematosus. Biomedicines.

Mercader-Salvans J, García-González M, et al | Antioxidants (Basel) | 2023

Relationship between Disease Characteristics and Circulating Interleukin 6 in a Well-Characterized Cohort of Patients with Systemic Lupus Erythematosus

Merino de Paz N, García-González M, et al | Antioxidants (Basel) | 2023

Relationship between Malondialdehyde Serum Levels and Disease Features in a Full Characterized Series of 284 Patients with Systemic Lupus Erythematosus.

Mocanu A, Bogos RA, et al | Diagnostics (Basel). | 2023

Pitfalls of Thrombotic Microangiopathies in Children: Two Case Reports and Literature Review.

Rajagopal V, Leksa N, et al | Blood Adv. | 2023

SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb.

Röth A, Berentsen S, et al | Hemasphere. | 2023


Schmouder R, Junge G, et al | Blood | 2023

A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101)

Simmons KT, Chan J, et al | Clin Immunol. | 2023

Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s

Stasi A, Fiorentino M, et al | BMC Med | 2023

Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project

Tang GQ, Tang Y, et al | Front Immunol. | 2023

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Ter Avest M, Bouwmeester RN, et al | Nephrol Dial Transplant. | 2023

Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective.

Urwyler P, Leimbacher M, et al |  Front Immunol | 2023

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.

Wong E, Nester C, et al | Kidney Int Rep. | 2023

Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

Zhang H, Rizk DV, et al | Kidney Int | 2023

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Aghababa H, Ting YT,et al | Virulence | 2022

Complement evasion factor (CEF), a novel immune evasion factor of Streptococcus pyogenes.

Biggs RM, Makou E, et al |  Invest Ophthalmol Vis Sci | 2022

An Evaluation of the Complement-Regulating Activities of Human Complement Factor H (FH) Variants Associated With Age-Related Macular Degeneration.

Braunger K, Ahn J, et al | Nat Commun | 2022

Structure and function of a family of tick-derived complement inhibitors targeting properdin.

De Marco Verissimo C, Jewhurst HL, et al |  PLoS Pathog | 2022

Fasciola hepatica is refractory to complement killing by preventing attachment of mannose binding lectin (MBL) and inhibiting MBL-associated serine proteases (MASPs) with serpins.

Eerhart MJ, Reyes JA, et al | Transplantation | 2022

Complement Blockade in Recipients Prevents Delayed Graft Function and Delays Antibody-mediated Rejection in a Nonhuman Primate Model of Kidney Transplantation.

Emtenani S, Holtsche MM, et al | Front Immunol | 2022

Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients

Fahnoe KC, Liu F, et al |  Front Immunol | 2022

Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue.

Garlich J, Cinier M, et al | Biomolecules | 2022

Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation.

Gauchel N, Rieder M, et al |  J Thromb Thrombolysis | 2022

Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease.

Henry BM, Sinkovits G,et al |  Front Med (Lausanne) | 2022

Complement Levels at Admission Reflecting Progression to Severe Acute Kidney Injury (AKI) in Coronavirus Disease 2019 (COVID-19): A Multicenter Prospective Cohort Study.

Hurler L, Toonen EJM, et al | Front Immunol | 2022

Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs.

Ihnatko M, Truchla I, et al |  Front Med (Lausanne) | 2022

Case Report: A Case of COVID Vaccine-Induced Thrombotic Thrombocytopenia Manifested as Pulmonary Embolism and Hemorrhagia. A First Reported Case From Slovakia.

Jang JH, Wong L, et al |  Blood Adv | 2022

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.

Khan AH, Pierce CO, et al | Eye (Lond) | 2022

The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD.

Khattab A, Rezola M, et al | Front Immunol | 2022

Hijacking the human complement inhibitor C4b-binding protein by the sporozoite stage of the Plasmodium falciparum parasite.

Kojima T, Inoue D, et al | Ren Fail | 2022

Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis

Kovala M, Seppälä M, Kaartinen K, et al | J Clin Med | 2022

Vascular Occlusion in Kidney Biopsy Is Characteristic of Clinically Manifesting Thrombotic Microangiopathy.

Landsem A, Emblem Å,et al |  Front Immunol | 2022

Complement C3b contributes to Escherichia coli-induced platelet aggregation in human whole blood.

Leatherdale A, Stukas S, et al | Med Microbiol Immunol | 2022

Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.

Lee HA, Jang H, et al |  Int J Clin Pharmacol Ther. | 2022

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.

Lupu L, Horst K, et al | Front Immunol | 2022

Simultaneous C5 and CD14 inhibition limits inflammation and organ dysfunction in pig polytrauma. Front Immunol. 2022

Muri L, Schubart A, et al |  Front Immunol | 2022

Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b.

Nagy ZA, Héja D, et al |  J Biol Chem | 2022

Synergy of protease-binding sites within the ecotin homodimer is crucial for inhibition of MASP enzymes and for blocking lectin pathway activation.

Nishimura JI, Ando K, et al | Haematologica | 2022

Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.

Ries JI, Heß M, et al | Front Immunol. | 2022

CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage.

Rollins RE, Wülbern J,et al |  Appl Environ Microbiol. | 2022

Utilizing Two Borrelia bavariensis Isolates Naturally Lacking the PFam54 Gene Array To Elucidate the Roles of PFam54-Encoded Proteins.

Roth A, Barcellini W, et al | Haematologica. | 2022

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.

Rysava R, Peiskerova M, et al | Front Immunol. | 2022

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report.

Röth A, Barcellini W, et al |  Ann Hematol. | 2022

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.

Röth A, Barcellini W, et al | Hemasphere. | 2022

P1538:Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results Following 9-week Washout Period in Phase 3 Cardinal Study (NCT03347396).

Röth A, Berentsen S, et al |  Blood | 2022

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Saito S, Tatsumoto N, Cao DY, et al |  Am J Physiol Renal Physiol. | 2022

Overexpressed angiotensin-converting enzyme in neutrophils suppresses glomerular damage in crescentic glomerulonephritis.

Sinkovits G, Schnur J, et al | Sci Rep | 2022

Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children.

Sodhi EU, Philpott HT, et al | Front Immunol | 2022

Sex-Differences and Associations Between Complement Activation and Synovial Vascularization in Patients with Late-Stage Knee Osteoarthritis.

Sridharan M, Go RS, Willrich MAV | Mayo Clin Proc Innov Qual Outcomes. | 2022

Clinical Utility and Potential Cost Savings of Pharmacologic Monitoring of Eculizumab for Complement-Mediated Thrombotic Microangiopathy.

Zhang Y, Goodfellow RX, et al | Front Immunol. | 2022

Complement Factor I Variants in Complement-Mediated Renal Diseases.

Askarian F, Uchiyama S,et al | Nat Commun | 2021

The lytic polysaccharide monooxygenase CbpD promotes Pseudomonas aeruginosa virulence in systemic infection.

Breville G, Zamberg I,et al | Front Immunol | 2021

Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies.

Charitos P, Heijnen IAFM, et al | Front Immunol | 2021

Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.

Chung WY, Pollard CA, et al | Ann Transl Med | 2021

A comparison of the inflammatory response following autologous compared with allogenic islet cell transplantation.

Denisov SS, Ippel JH, et al |  J Biol Chem | 2021

Molecular basis of anticoagulant and anticomplement activity of the tick salivary protein Salp14 and its homologs.

Emmons TR, Giridharan T, et al | Cancer Immunol Res | 2021

Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer.

Flude BM, Nannetti G, et al | Viruses | 2021

Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections

Garam N, Cserhalmi M, et al | Front Immunol | 2021

FHR-5 Serum Levels and CFHR5 Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy.

Henry BM, Szergyuk I, et al |  J Med Virol | 2021

Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state. J Med Virol. 2021

Holt MF, Michelsen AE, et al | Front Immunol | 2021

The Alternative Complement Pathway Is Activated Without a Corresponding Terminal Pathway Activation in Patients With Heart Failure.

Horváth O, Kelen K, et al | Pediatr Nephrol. | 2021

Atypical HUS and Crohn's disease-interference of intestinal disease activity with complement-blocking treatment.

Kaartinen K, Vuoti S, et al | PLoS One | 2021

Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.

Keshari RS, Popescu NI, et al | Proc Natl Acad Sci U S A | 2021

Complement C5 inhibition protects against hemolytic anemia and acute kidney injury in anthrax peptidoglycan-induced sepsis in baboons.

Langereis JD, van der Molen RG, et al |  Clin Transl Immunology | 2021

Complement factor D haplodeficiency is associated with a reduced complement activation speed and diminished bacterial killing.

Lipcsey M, Persson B, et al | Front Immunol | 2021

The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System.

Macpherson A, Laabei M, et al | Elife | 2021

The allosteric modulation of complement C5 by knob domain peptides.

Pollack S, Eisenstein I, et al | Front Immunol | 2021

A Novel Homozygous In-Frame Deletion in Complement Factor 3 Underlies Early-Onset Autosomal Recessive Atypical Hemolytic Uremic Syndrome - Case Report.

Risitano AM, Kulasekararaj AG, et al | Haematologica | 2021

Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.

Sinkovits G, Mező B, et al | Front Immunol | 2021

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.

Smolag KI, Fager Ferrari M, et al |  Front Immunol | 2021

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE.

Stasi A, Franzin R, Divella C, et al | Front Immunol | 2021

PMMA-Based Continuous Hemofiltration Modulated Complement Activation and Renal Dysfunction in LPS-Induced Acute Kidney Injury.

Storm BS, Christiansen D, Fure H, et al | J Immunol | 2021

Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood.

Tølbøll Sørensen AL, Rolland M, et al | Blood Adv. | 2021

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2.

Van de Walle I, Silence K, et al | J Allergy Clin Immunol | 2021

ARGX-117, a therapeutic complement inhibiting antibody targeting C2

van Erp IAM, van Essen TA, et al | Trials | 2021

Safety and efficacy of C1-inhibitor in traumatic brain injury (CIAO@TBI): study protocol for a randomized, placebo-controlled, multi-center trial.

Willrich MAV, Ladwig PM, et al | J Immunol Methods | 2021

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Wu LP, Ficker M, Christensen JB, et al | Nat Commun | 2021

Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking.

Wymann S, Dai Y, Nair AG, Cao H, et al | J Biol Chem | 2021

A novel soluble complement receptor 1 fragment with enhanced therapeutic potential.

Zecevic M, Minic A, et al | Front Pediatr | 2021

Case Report: Early Onset Systemic Lupus Erythematosus Due to Hereditary C1q Deficiency Treated With Fresh Frozen Plasma.

Aleš Rigler A, Večerić-Haler Ž, et al |  J Int Med Res | 2020

Exploring the role of the complement system, endothelial injury, and microRNAs in thrombotic microangiopathy after kidney transplantation.

Bernth Jensen JM, Laursen NS, et al |  Immunology | 2020

Complement activation by human IgG antibodies to galactose-α-1,3-galactose.

Chung WY, Pollard CA, et al | Ann Transl Med | 2020

Pilot study: deficiency of mannose-binding lectin-dependent lectin pathway, a novel modulator in outcome from pancreatic islet auto-transplantation.

Danobeitia JS, Zens TJ, et al |  Am J Transplant | 2020

Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.

Dellepiane RM, Baselli LA, et al | Medicina (Kaunas) | 2020

Hereditary Deficiency of the Second Component of Complement: Early Diagnosis and 21-Year Follow-Up of a Family.

Grinde D, Øverland T, et al |  J Clin Immunol | 2020

Complement Activation in 22q11.2 Deletion Syndrome.

Haljasmägi L, Salumets A,et al |  Sci Rep | 2020

Longitudinal proteomic profiling reveals increased early inflammation and sustained apoptosis proteins in severe COVID-19.

Holter JC, Pischke SE, et al | Proc Natl Acad Sci U S A | 2020

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.

LaFon DC, Thiel S, et al |  Immun Ageing | 2020

Classical and lectin complement pathways and markers of inflammation for investigation of susceptibility to infections among healthy older adults.

Lindholm M, Metsäniitty M, et al | J Oral Microbiol | 2020

Outer membrane vesicle-mediated serum protection in Aggregatibacter actinomycetemcomitans.

Martin M, Trattner R, et al |  Front Immunol | 2020

Plasma C4d Correlates With C4d Deposition in Kidneys and With Treatment Response in Lupus Nephritis Patients.

Mezö B, Horváth O, et al | Front Med (Lausanne). | 2020

Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation.

Mező B, Reindl-Schwaighofer R, et al | Transplant Direct | 2020

High-activity Classical and Alternative Complement Pathway Genotypes-Association With Donor-specific Antibody-triggered Injury and Renal Allograft Survival.

Michelis R, Tadmor T,et al |  PLoS One | 2020

Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway.

O'Brien ME, Fee L, et al |  Thorax | 2020

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.

Reichhardt MP, Johnson S, et al | Proc Natl Acad Sci U S A | 2020

An inhibitor of complement C5 provides structural insights into activation.

Talsma DT, Poppelaars F, et al |  Front Immunol | 2020

MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides.

Taylor S, Whitfield M, et al |  J Immunol | 2020

The Metalloproteinase ADAMTS5 Is Expressed by Interstitial Inflammatory Cells in IgA Nephropathy and Is Proteolytically Active on the Kidney Matrix.

van den Heuvel LP, van de Kar NCAJ, et al | Cell Mol Immunol | 2020

The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment.

Vogt S, Trendelenburg M, et al | Front Immunol | 2020

Local and Systemic Concentrations of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases.

Barkai LJ, Sipter E, et al |  Front Immunol | 2019

Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus.

Bartoszek D, Mazanowska O, et al | Arch Immunol Ther Exp | 2019

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Bartoszek D, Mazanowska O,et al | Arch Immunol Ther Exp (Warsz). | 2019

Post-transplant Alternative Complement Pathway Activation Influences Kidney Allograft Function.

Bradford CM, McDonnell T,et al | ACR Open Rheumatol | 2019

Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate.

Fridkis-Hareli M, Storek M, et al | Mol Immunol | 2019

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

Garam N, Prohászka Z, et al | Orphanet J Rare Dis | 2019

C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy.

Hodyra-Stefaniak K, et al | Microb Biotechnol | 2019

Bacteriophages engineered to display foreign peptides may become short-circulating phages.

Kusner LL, Yucius K, et al | Mol Ther Methods Clin Dev | 2019

Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis.

Li Y, Zhao Q, et al | Trauma Surg Acute Care Open | 2019

Early complementopathy predicts the outcomes of patients with trauma.

Mai K, Boldt A, et al | Anal Cell Pathol (Amst) | 2019

Immunological Alterations due to Hemodialysis Might Interfere with Early Complications in Renal Transplantation.

Mohebnasab M, Eriksson O, et al | Front Immunol | 2019

Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics.

Panwar HS, Ojha H, et al | Proc Natl Acad Sci U S A | 2019

Molecular engineering of an efficient four-domain DAF-MCP chimera reveals the presence of functional modularity in RCA proteins.

Preisker S, Brethack AK, et al | Cells | 2019

Crohn's Disease Patients in Remission Display an Enhanced Intestinal IgM⁺ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System.

Pérez-Alós L, Bayarri-Olmos R, et al | FASEB J | 2019

Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade.

Szakács D, Kocsis A, et al | J Biol Chem | 2019

Novel MASP-2 inhibitors developed via directed evolution of human TFPI1 are potent lectin pathway inhibitors.

Trojnar E, Józsi M, et al |  Front Immunol | 2019

Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.

Vercauteren KOA, Lambrecht S, Delanghe J | Biochem Med (Zagreb) | 2019

Preanalytical classical and alternative complement pathway activity loss.

Wahid AA, Doekhie A, et al | Sci Rep | 2019

Ensilication Improves the Thermal Stability of the Tuberculosis Antigen Ag85b and an Sbi-Ag85b Vaccine Conjugate.

Wijnsma KL, Duineveld C, et al | Pediatr Nephrol | 2019

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Yang Y, Back CR, et al | Front Immunol | 2019

Utilization of Staphylococcal Immune Evasion Protein Sbi as a Novel Vaccine Adjuvant.

Zitur LJ, Chlebeck PJ, et al | Transplantation | 2019

Brain Death Enhances Activation of the Innate Immune System and Leads to Reduced Renal Metabolic Gene Expression.

Bartko J, Schoergenhofer C, et al | Clin Pharmacol Ther | 2018

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.

Bartoszek D, Mazanowska O, et al | Transplant Proc | 2018

Functional Activity of the Complement System in Deceased Donors in Relation to Kidney Allograft Outcome

Bjerre A, Bergseth G, et al | Case Rep Nephrol | 2018

Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome

Gaya da Costa M, Poppelaars F, et al | Front Immunol | 2018

Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population

Harhala M, Nelson DC, et al | Viruses | 2018

Safety Studies of Pneumococcal Endolysins Cpl-1 and Pal.

Hertz CE, Bayarri-Olmos R, et al |  Front Immunol | 2018

Chimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities. Front Immunol. 2018

Høiland II, Liang RA, et al | Thromb Res | 2018

Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism

Klassert TE, Goyal S, Stock M,et al | Front Immunol | 2018

AmpliSeq Screening of Genes Encoding the C-Type Lectin Receptors and Their Signaling Components Reveals a Common Variant in MASP1 Associated with Pulmonary Tuberculosis in an Indian Population.

Lung T, Matozan K, et al | Diagnosis (Berl) | 2018

Complement systems C4, C3 and CH50 not subject to a circadian rhythm

Macpherson A, Liu X, et al |  J Biol Chem. | 2018

The rational design of affinity-attenuated OmCI for the purification of complement C5.

Michelfelder S, Fischer F, et al | J Am Soc Nephrol | 2018

The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential

Mutti M, Ramoni K, et al |  Front Immunol. | 2018

A New Tool for Complement Research: In vitro Reconstituted Human Classical Complement Pathway.

Nada R, Kumar A, et al | Kidney Int Rep | 2018

Renal and Pulmonary Dense Deposit Disease Presenting as Pulmonary-Renal Syndrome

Shende R, Wong SSW, et al | J Biol Chem. 2018 | 2018

Aspergillus fumigatus conidial metalloprotease Mep1p cleaves host complement proteins

Siljan WW, Holter JC, et al | Open Forum Infect Dis | 2018

Low Levels of Immunoglobulins and Mannose-Binding Lectin Are Not Associated With Etiology, Severity, or Outcome in Community-Acquired Pneumonia.

Spirig R, Campbell IK, et al | J Immunol. | 2018

rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.

Timmermans SAMEG, Abdul-Hamid MA, et al |  J Am Soc Nephrol | 2018

C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.

Willrich MAV, Andreguetto BD, et al | J Immunol Methods | 2018

The impact of eculizumab on routine complement assays

Foghmar C, Brøns C, et al |  Sci Rep | 2017

Complement factors C4 and C3 are down regulated in response to short term overfeeding in healthy young men.

Fukuzawa T, Sampei Z, et al | Sci Rep | 2017

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.

Gustavsen A, Skattum L, et al | Medicine (Baltimore) | 2017

Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report.

Harboe M, Johnson C, et al | Proc Natl Acad Sci U S A | 2017

Properdin binding to complement activating surfaces depends on initial C3b deposition.

Hellerud BC, Orrem HL, et al |  J Intensive Care | 2017

Combined inhibition of C5 and CD14 efficiently attenuated the inflammatory response in a porcine model of meningococcal sepsis.

Kemna MJ, Plomp R, et al |  EBioMedicine | 2017

Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis.

Konar M, Granoff DM | Blood | 2017

Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Liu J, Xie J, et al | Sci Rep | 2017

Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis.

Michelfelder S, Parsons J, et al |  J Am Soc Nephrol | 2017

Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.

Mühlbacher J, Jilma B, et al |  Transplantation | 2017

Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial.

Pischke SE, Gustavsen A, et al | Basic Res Cardiol | 2017

Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function.

Röttgerding F, Wagemakers A, et al |  Sci Rep | 2017

Immune evasion of Borrelia miyamotoi: CbiA, a novel outer surface protein exhibiting complement binding and inactivating properties.

Szijártó V, Guachalla LM, et al | Virulence | 2017

Endotoxin neutralization by an O-antigen specific monoclonal antibody: A potential novel therapeutic approach against Klebsiella pneumoniae ST258.

van Dijk EHC, Tsonaka R, et al | PLoS One | 2017

Systemic complement activation in central serous chorioretinopathy.

Wehling C, Amon O, et al | Clin Exp Immunol | 2017

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Westra D, Volokhina EB, et al | Pediatr Nephrol | 2017

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome

Yuan X, Gavriilaki E, et al |  Haematologica | 2017

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Zhang Y, Meyer NC, et al |  Am J Kidney Dis | 2017

C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

Zhang Z, Zhang X, et al |  Redox Biol | 2017

Glutathione inhibits antibody and complement-mediated immunologic cell injury via multiple mechanisms.

Canney M, O'Hara PV, et al | Clin J Am Soc Nephrol | 2016

Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease.

Dellepiane RM, Dell'Era L, et al | Orphanet J Rare Dis | 2016

Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosis.

Dobó J, Szakács D, et al | Sci Rep | 2016

MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked.

Hutu DP, Tuddenham E, et al | Clin Exp Immunol | 2016

First steps in the standardization of immunoglobulin IgG myeloperoxidase-anti-neutrophil cytoplasmic antibody measurements.

Jore MM, Johnson S, et al | Nat Struct Mol Biol | 2016

Structural basis for therapeutic inhibition of complement C5

Keizer MP, Kamp AM, et al | Front Immunol | 2016

The High Prevalence of Functional Complement Defects Induced by Chemotherapy.

Pietrocola G, Rindi S, et al |  J Immunol | 2016

The Group B Streptococcus-Secreted Protein CIP Interacts with C4, Preventing C3b Deposition via the Lectin and Classical Complement Pathways.

Poppelaars F, Damman J, et al | Clin Exp Immunol | 2016

New insight into the effects of heparinoids on complement inhibition by C1-inhibitor

Schmidt CQ, Harder MJ, et al |  Immunobiology | 2016

Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Scietti L, Sampieri K, et al | Sci Rep | 2016

Exploring host-pathogen interactions through genome wide protein microarray analysis.

van Schaarenburg RA, Magro-Checa C, et al | Front Immunol | 2016

C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus.

Gatault P, Brachet G, et al | Mabs | 2015

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.

Hein E, Munthe-Fog L, et al | Clin Exp Immunol | 2015

Heparin-coated cardiopulmonary bypass circuits selectively deplete the pattern recognition molecule ficolin-2 of the lectin complement pathway in vivo.

Ingels H, Schejbel L, et al | Pediatr Infect Dis J | 2015

Immunodeficiency among children with recurrent invasive pneumococcal disease

Mulley G, Beeton ML, et al | PLoS One | 2015

From Insect to Man: Photorhabdus Sheds Light on the Emergence of Human Pathogenicity.

Rossio R, Lotta LA, et al | Haematologica | 2015

A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.

Volokhina EB, van de Kar NC, et al | Clin Immunol | 2015

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome

Volokhina EB, Westra D,et al | Clin Exp Immunol | 2015

Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission.

Brodszki N, Jönsson G, et al | BMC Immunol | 2014

Primary immunodeficiency in infection-prone children in southern Sweden: occurrence, clinical characteristics and immunological findings

Brunner J, Giner T, Wuerzner R | Pediatr Rheumatol Online J | 2014

Complement analysis reveals new biomarkers in patients with juvenile idiopathic arthritis.

Cugno M, Gualtierotti R, et al | J Thromb Haemost | 2014

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

Gaschignard J, Levy C,et al | Clin Infect Dis | 2014

Invasive pneumococcal disease in children can reveal a primary immunodeficiency.

Korir JC, Nyakoe NK, et al | PLoS One | 2014

Complement activation by merozoite antigens of Plasmodium falciparum

Olde Nordkamp MJ, et al |  J Innate Immun | 2014

Inhibition of the classical and lectin pathway of the complement system by recombinant LAIR-2. J Innate Immun. 2014

Roos A, Wieslander J | Methods Mol Biol | 2014

Evaluation of complement function by ELISA

van Kessel DA, Hoffman TW, et al | Clin Exp Immunol | 2014

Response to pneumococcal vaccination in mannose-binding lectin-deficient adults with recurrent respiratory tract infections.

Feng S, Eyler SJ, et al | Blood | 2013

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Hallström T, Siegel C, et al | mBio | 2013

CspA from Borrelia burgdorferi inhibits the terminal complement pathway

Rusai K, Zaller V, et al | CEN Case Rep | 2013

A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency

Ruuskanen O, Nurkka A, et al | Clin Exp Immunol | 2013

Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up

Severino V, Malorni L, et al |  PLoS One | 2013

An integrated approach based on multiplexed protein array and iTRAQ labeling for in-depth identification of pathways associated to IVF outcome

Tsao N, Cheng MH, et al | PLoS One | 2013

Determining antibody-binding site of streptococcal pyrogenic exotoxin B to protect mice from group a streptococcus infection.

Zhang Y, Nester CM, et al |  J Am Soc Nephrol | 2013

Soluble CR1 therapy improves complement regulation in C3 glomerulopathy

Barthel D, Schindler S, Zipfel PF |  J Biol Chem | 2012

Plasminogen is a complement inhibitor

Cazander G, Jukema GN, Nibbering PH |  Clin Dev Immunol | 2012

Complement activation and inhibition in wound healing

Harboe M, Garred P, et al | J Immunol | 2012

The role of properdin in zymosan- and Escherichia coli-induced complement activation.

Helminen M, Seitsonen S, et al | Scand J Immunol | 2012

A novel mutation W388X underlying properdin deficiency in a Finnish family.

Héja D, Harmat V, et al |  J Biol Chem | 2012

Monospecific inhibitors show that both mannan-binding lectin-associated serine protease-1 (MASP-1) and -2 Are essential for lectin pathway activation and reveal structural plasticity of MASP-2.

Héja D, Kocsis A, et al | Proc Natl Acad Sci U S A | 2012

Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2.

Idorn T, Schejbel L, et al | BMC Nephrol | 2012

Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives: a case report.

Inoshita H, Ohsawa I, et al | Clin Kidney J | 2012

An analysis of functional activity via the three complement pathways during hemodialysis sessions: a new insight into the association between the lectin pathway and C5 activation.

Mika A, Reynolds SL, et al | PLoS Negl Trop Dis | 2012

Complement inhibitors from scabies mites promote streptococcal growth--a novel mechanism in infected epidermis?

Nilsson B, Ekdahl KN | Clin Dev Immunol | 2012

Complement diagnostics: concepts, indications, and practical guidelines

Reichhardt MP, Loimaranta V, et al | Front Immunol | 2012

The salivary scavenger and agglutinin binds MBL and regulates the lectin pathway of complement in solution and on surfaces.

Rødland EK, Ueland T, et al | BMC Infect Dis. | 2012

Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis.

Sethi S, Fervenza FC, et al |  Kidney Int. | 2012

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up

Zhang Y, Meyer NC, et al | Clin J Am Soc Nephrol | 2012

Causes of alternative pathway dysregulation in dense deposit disease

Abrera-Abeleda MA, Nishimura C, et al |  J Am Soc Nephrol | 2011

Allelic variants of complement genes associated with dense deposit disease

Barratt-Due A, Thorgersen EB, et al |  J Immunol | 2011

Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans

Bergseth G, Lambris JD, et al | Ann Thorac Surg | 2011

Artificial surface-induced inflammation relies on complement factor 5: proof from a deficient person.

Fridkis-Hareli M, Storek M, et al | Blood | 2011

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

Ilyas R, Wallis R, et al |  Immunobiology | 2011

High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus

Maga TK, Meyer NC, et al | Nephrol Dial Transplant | 2011

A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome

Martel C, Cointe S, et al | PLoS One | 2011

Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets

Palarasah Y, Nielsen C, et al | Clin Exp Immunol | 2011

Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system.

Sethi S, Fervenza FC, et al | Clin J Am Soc Nephrol | 2011

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.

Smeets B, Kuppe C,et al | J Am Soc Nephrol | 2011

Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis.

Abdgawad M, Gunnarsson L, et al | Clin Exp Immunol | 2010

Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression.

Castellano G, Melchiorre R, et al | Am J Pathol | 2010

Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage.

Inoshita H, Ohsawa I,et al | BMC Nephrol | 2010

Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis

Orth D, Ehrlenbach S, et al | Infect Immun | 2010

EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5

Selga D, Segelmark M, et al | Clin Exp Immunol | 2010

Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.

Kallio SP, Jakkula E, et al | Hum Mol Genet | 2009

Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet. 2009

Lappegård KT, Christiansen D, et al | Proc Natl Acad Sci U S A. | 2009

Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature.

Nyakoe NK, Taylor RP, et al | Malar J | 2009

Complement consumption in children with Plasmodium falciparum malaria.

Salvesen B, Mollnes TE | Mol Immunol | 2009

Pathway-specific complement activity in pigs evaluated with a human functional complement assay

Burman JD, Leung E,et al |  J Biol Chem | 2008

Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus.

Hamad I, Christy Hunter A, et al | Mol Immunol | 2008

Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover.

Ito-Ihara T, Muso E, et al | Clin Exp Rheumatol | 2008

A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe

Kimura Y, Miwa T, et al |  Blood | 2008

Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.

Kuo CF, Lin YS, et al |  Infect Immun | 2008

Degradation of complement 3 by streptococcal pyrogenic exotoxin B inhibits complement activation and neutrophil opsonophagocytosis

Upadhyay A, Burman JD,et al | J Biol Chem. | 2008

Structure-function analysis of the C3 binding region of Staphylococcus aureus immune subversion protein Sbi

Varga L, Széplaki G, et al | Clin Exp Immunol | 2008

Depressed activation of the lectin pathway of complement in hereditary angioedema

Harboe M, Garred P, et al | Clin Exp Immunol | 2006

Design of a complement mannose-binding lectin pathway-specific activation system applicable at low serum dilutions.

Selander B, Mårtensson U, et al | J Clin Invest | 2006

Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2.

Thiel S, Frederiksen PD, Jensenius JC | Mol Immunol | 2006

Clinical manifestations of mannan-binding lectin deficiency.

Carlsson M, Sjöholm AG, et al |  Clin Exp Immunol | 2005

Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship.

Fevang B, Mollnes TE, et al |  Clin Exp Immunol | 2005

Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis.

Wieslab Diagnostic Services

Smargianaki S, Elmér E, et al | J Immunol Res. | 2024

Disease Activity and Tendency to Relapse in ANCA-Associated Vasculitis Are Reflected in Neutrophil and Intermediate Monocyte Frequencies

Bitoun S, Hässler S, et al |  JAMA Netw Open | 2023

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.

Holzinger JM, Toelge M, Werner M, et al | Elife | 2023

Scorpionfish BPI is highly active against multiple drug-resistant Pseudomonas aeruginosa isolates from people with cystic fibrosis

Kosek S, Persson B et al. | Acta Scan | 2023

Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

Rathmann J, Segelmark M, et al | RMD Open | 2023

Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study.

Sirago G, Candia J, et al | Biology (Basel) | 2023

Upregulation of Sarcolemmal Hemichannels and Inflammatory Transcripts with Neuromuscular Junction Instability during Lower Limb Unloading in Humans.

Johnsson M, Asztely F, et al | Ann Clin Transl Neurol | 2022

SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder.

Sarto F, Stashuk DW, et al |  J Physiol | 2022

Effects of short-term unloading and active recovery on human motor unit properties, neuromuscular junction transmission and transcriptomic profile.

Uhlin F, Szpirt W, et al | J Am Soc Nephrol | 2022

Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study.

Bejerot S, Hylén U, et al | Front Psychiatry | 2021

Joint Hypermobility in Paediatric Acute-Onset Neuropsychiatric Syndrome-A Preliminary Case-Control Study.

Jia H, Harikumar P, et al | Biomolecules | 2021

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab.

Lagerqvist N, Maleki KT, et al |  Sci Rep | 2021

Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers.

Elmér E, Smargianaki S, et al | J Immunol Res | 2020

Increased Frequencies of Switched Memory B Cells and Plasmablasts in Peripheral Blood from Patients with ANCA-Associated Vasculitis.

Hässler S, Bachelet D, et al | PLoS Med | 2020

A prospective multicohort study of the ABIRISK consortium.

Hesselmark E, Bejerot S | BJPsych Open | 2019

Clinical features of paediatric acute-onset neuropsychiatric syndrome: findings from a case- control study.

Jonsson DI, Sveinsson O, et al | Neurology | 2019

Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study.

Sveinsson O, Al Nimer F, Piehl F | BMJ Case Rep | 2019

Morvan's syndrome treated successfully with rituximab and lacosamide.

El-Hussuna A, Qvist N, et al | BMC Surg | 2018

No effect of anti-TNF-α agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study.

Jönsson N, Erlandsson E, et al | Mediators Inflamm | 2018

Monocyte Chemoattractant Protein-1 in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis: Biomarker Potential and Association with Polymorphisms in the MCP-1 and the CC Chemokine Receptor-2 Gene.

Mäkelä KM, Hietaharju A, et al | Front Neurol | 2018

Clinical Management of Epilepsy With Glutamic Acid Decarboxylase Antibody Positivity: The Interplay Between Immunotherapy and Anti-epileptic Drugs.

Fernström J, Westrin Å, et al | PLoS One | 2017

Six autoantibodies associated with autoimmune encephalitis are not detectable in the cerebrospinal fluid of suicide attempters.

Eftimiadi C, Eftimiadi G, Vinai P | Front Psychiatry | 2016

Staphylococcus aureus Colonization Modulates Tic Expression and the Host Immune Response in a Girl with Tourette Syndrome.

Johansson ÅC, Ohlsson S, et al | Arthritis Res Ther | 2016

Impaired phagocytosis and reactive oxygen species production in phagocytes is associated with systemic vasculitis.

Ohlsson S, Bakoush O, et al | Mediators Inflamm | 2009

Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.

Ohlsson S, Hellmark T, et al | Clin Exp Immunol | 2005

Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis.

Ohlsson S, Wieslander J, Segelmark M | Mediators Inflamm | 2004

Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome? Mediators Inflamm. 2004

Ohlsson S, Wieslander J, Segelmark M | Clin Exp Immunol | 2003

Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.

Persson U, Truedsson L, et al |  Clin Exp Immunol | 1999

C3 and C4 allotypes in anti-neutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis.

Trier K, Olsen EB, et al | Br J Ophthalmol | 1999

Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine.


Cyranka L, Mariegaard I, et al | J Innate Immun | 2023

Functional analysis of a novel complement C5a receptor 1-blocking monoclonal antibody

Jung YE, Lee KW, Cho JH, et al | Sci Rep | 2023

Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency

Kinne AS, Tillman EJ, et al | J Pharm Biomed Anal | 2023

Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin

Lallemand, C., Fernando-Miguel, et al | Medical Research Archives | 2023

Analysis of Bevacizumab Activity Following Treatment Patients with Ovarian Cancer or Glioblastoma

Lallemand, C., Fernando-Miguel, et al | Medical Research Archives | 2023

Analysis of Bevacizumab Activity Following Treatment Patients with Ovarian Cancer or Glioblastoma

Guo K, Barrett BS, Morrison JH, et al | Proc Natl Acad Sci U S A | 2022

Interferon resistance of emerging SARS-CoV-2 variants

Guo K, Shen G, Kibbie J, et al | PLoS Pathog | 2022

Qualitative Differences Between the IFNα subtypes and IFNβ Influence Chronic Mucosal HIV-1 Pathogenesis 

Lee CG, Kim T, Hong S, et al | Front Pharmacol | 2021

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

Kharlamova N, Hermanrud C, Dunn N, et al | Front Immunol | 2020

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier 

Lallemand C, Ferrando-Miguel R, Auer M, et al | Front Immunol | 2020

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma 

Sjögren J, Lood R, Nägeli A. | Glycobiology | 2020

On enzymatic remodeling of IgG glycosylation; unique tools with broad applications 

Meier S, Bohnacker S, Klose CJ, et al | Nat Commun | 2019

The molecular basis of chaperone-mediated interleukin 23 assembly control 

Mojtahed Poor S, Ulshöfer T, Gabriel LA, et al | Clin Exp Immunol | 2019

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab 

Hyun JW, Kim G, Kim Y, et al | J Clin Neurol | 2018

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis 

Lallemand C, Liang F, Staub F, et al | J Immunol Res | 2017

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies 

Link J, Ramanujam R, Auer M, et al | PLoS One | 2017

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results 

Bachelet D, Hässler S, Mbogning C, et al | PLoS One | 2016

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis 

Hermanrud C, Ryner M, Luft T, Jensen PE, et al | J Immunol Methods | 2016

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Jacobson JM, Bosinger SE, Kang M, et al | AIDS Res Hum Retroviruses | 2016

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1 AIDS Res Hum Retroviruses

Pogue SL, Taura T, Bi M, et al | PLoS One | 2016

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity 

van Bezooijen JS, Koch BC, et al | Ther Drug Monit | 2016

Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

Aalbers CJ, Bevaart L, Loiler S, et al | PLoS One | 2015

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis 

Eng GP, Bendtzen K, Bliddal H, et al | Arthritis | 2015

Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study 

Hermanrud C, Ryner ML, et al |  J Interferon Cytokine Res | 2014

Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point

Mora J, Given Chunyk A, et al | AAPS J | 2014

Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing

Cardillo TM, Trisal P, et al | BMC Cancer | 2013

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro 

Hardy GA, Sieg S, Rodriguez B, et al | PLoS One | 2013

Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers

Wadhwa M, Subramanyam M, Goelz S, et al |  J Interferon Cytokine Res | 2013

Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β

Tattermusch S, Skinner JA, Chaussabel D, et al | PLoS Pathog | 2012

Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy

Rossi EA, Rossi DL, Cardillo TM, et al | Blood | 2011

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers 

Rossi EA, Goldenberg DM, et al | Blood | 2009

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas